Skip to main content
Erschienen in: World Journal of Surgery 6/2014

01.06.2014

Role of Ki-67 Proliferation Index in the Assessment of Patients with Neuroendocrine Neoplasias Regarding the Stage of Disease

verfasst von: H. C. Miller, P. Drymousis, R. Flora, R. Goldin, D. Spalding, A. Frilling

Erschienen in: World Journal of Surgery | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Neuroendocrine neoplasias (NEN) of the gastroenteropancreatic (GEP) system frequently present with metastatic deposits. The proliferation marker Ki-67 is used for diagnosis and to assess the prognosis of disease. The aim of our study was to evaluate the usefulness of Ki-67 % in the assessment of NEN patients with regard to their disease stage in clinical practice. Additionally, a comparative analysis of Ki-67 levels among different sites of disease was performed.

Methods

This retrospective study included patients with GEP NEN referred to our center from 2010 to 2012. The NEN diagnosis was confirmed by standard histopathology. Ki-67 immunohistochemistry was done on paraffin-embedded sections using an automated Leica immunohistochemistry machine. NEN grading was carried out according to European Neuroendocrine Tumor Society recommendations (low grade [G1] to intermediate grade [G2], well to moderately differentiated neuroendocrine neoplasms; high-grade [G3], moderately to poorly differentiated neuroendocrine neoplasms). Results of tumor staging and grading were correlated. In a subgroup of cases, comparative analysis of Ki-67 levels in different sites of disease was carried out.

Results

One hundred sixty-one GEP NEN patients were included in the study. Metastatic disease was seen in 46.1 % (53/115) of G1 tumors, 77.8 % (28/36) of G2 tumors, and 100 % of (10/10) G3 tumors (p = 0.0002). When stratified according to primary tumor site, metastatic disease was documented in 42.9 % (36/84) of patients with pancreatic NEN and in 91.9 % (34/37) of those with small intestinal primary. Stage IV metastatic disease was present in 27.8 % (32/115) and 72.2 % (26/36) of the G1 and G2 tumors, respectively, and in 90 % (9/10) of the G3 tumors. Assessment of the Ki-67 index for a subset of cases at metastatic sites as well as the primary tumor site showed discrepancies in 35.3 % cases. In 7/9 (77.8 %) patients with liver metastases, Ki-67 % was higher in the liver lesions than in the primary tumor.

Conclusions

Patients with GEP NEN exhibiting a high Ki-67 proliferation index present with metastatic disease in the vast majority of cases. Depending upon the primary tumor site, metastases are to be expected also in tumors with low Ki-67 %, although they are considered less aggressive. Different disease sites may express heterogeneous Ki-67 levels.
Literatur
1.
Zurück zum Zitat Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1):1–18 viiPubMedCrossRef Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1):1–18 viiPubMedCrossRef
2.
Zurück zum Zitat Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072PubMedCrossRef Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072PubMedCrossRef
3.
Zurück zum Zitat Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V et al (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794–1803PubMedCrossRef Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V et al (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794–1803PubMedCrossRef
4.
Zurück zum Zitat Lombard-Bohas C, Mitry E, O’Toole D, Louvet C, Pillon D, Cadiot G et al (2009) Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 89(2):217–222PubMedCrossRef Lombard-Bohas C, Mitry E, O’Toole D, Louvet C, Pillon D, Cadiot G et al (2009) Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 89(2):217–222PubMedCrossRef
5.
Zurück zum Zitat Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D et al (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16(3):885–894PubMedCrossRef Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D et al (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16(3):885–894PubMedCrossRef
6.
Zurück zum Zitat Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B (2008) Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Research 14(23):7798–7803CrossRef Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B (2008) Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Research 14(23):7798–7803CrossRef
7.
Zurück zum Zitat Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Muller-Nordhorn J et al (2011) Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117(15):3332–3341PubMedCrossRef Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Muller-Nordhorn J et al (2011) Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117(15):3332–3341PubMedCrossRef
8.
Zurück zum Zitat Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104(10):764–777PubMedCrossRef Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104(10):764–777PubMedCrossRef
9.
Zurück zum Zitat Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP et al (2000) Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 31(10):1255–1265PubMedCrossRef Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP et al (2000) Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 31(10):1255–1265PubMedCrossRef
10.
Zurück zum Zitat Hotta K, Shimoda T, Nakanishi Y, Saito D (2006) Usefulness of Ki-67 for predicting the metastatic potential of rectal carcinoids. Pathol Int 56(10):591–596PubMedCrossRef Hotta K, Shimoda T, Nakanishi Y, Saito D (2006) Usefulness of Ki-67 for predicting the metastatic potential of rectal carcinoids. Pathol Int 56(10):591–596PubMedCrossRef
11.
Zurück zum Zitat Jamali M, Chetty R (2008) Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 19(4):282–288PubMedCrossRef Jamali M, Chetty R (2008) Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 19(4):282–288PubMedCrossRef
12.
Zurück zum Zitat Rindi G, Kloppel G, Ahlman H, Caplin M, Couvelard A, de Herder WW et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395–401PubMedCentralPubMedCrossRef Rindi G, Kloppel G, Ahlman H, Caplin M, Couvelard A, de Herder WW et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395–401PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM et al (2007) TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757–762PubMedCrossRef Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM et al (2007) TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757–762PubMedCrossRef
14.
Zurück zum Zitat Bosman FT, World Health Organization, International Agency for Research on Cancer (2010) WHO classification of tumours of the digestive system, 4th edn. International Agency for Research on Cancer, Lyon, p 417 Bosman FT, World Health Organization, International Agency for Research on Cancer (2010) WHO classification of tumours of the digestive system, 4th edn. International Agency for Research on Cancer, Lyon, p 417
15.
Zurück zum Zitat Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T (2013) A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer 108(9):1838–1845PubMedCrossRef Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T (2013) A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer 108(9):1838–1845PubMedCrossRef
16.
Zurück zum Zitat Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23(6):824–833PubMedCrossRef Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23(6):824–833PubMedCrossRef
17.
Zurück zum Zitat Hentic O, Couvelard A, Rebours V, Zappa M, Dokmak S, Hammel P et al (2011) Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer 18(1):51–59PubMedCrossRef Hentic O, Couvelard A, Rebours V, Zappa M, Dokmak S, Hammel P et al (2011) Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer 18(1):51–59PubMedCrossRef
18.
Zurück zum Zitat Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R et al (2012) Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 48(11):1608–1615PubMedCrossRef Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R et al (2012) Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 48(11):1608–1615PubMedCrossRef
19.
Zurück zum Zitat Dhall D, Mertens R, Bresee C, Parakh R, Wang HL, Li M et al (2012) Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum Pathol 43(4):489–495PubMedCrossRef Dhall D, Mertens R, Bresee C, Parakh R, Wang HL, Li M et al (2012) Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum Pathol 43(4):489–495PubMedCrossRef
20.
Zurück zum Zitat La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A et al (2009) Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 40(1):30–40PubMedCrossRef La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A et al (2009) Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 40(1):30–40PubMedCrossRef
21.
Zurück zum Zitat Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D et al (2009) Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 16(2):585–597PubMedCrossRef Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D et al (2009) Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 16(2):585–597PubMedCrossRef
22.
Zurück zum Zitat Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wangler B, Uebleis C et al (2012) The role of 68 Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med 53(11):1686–1692PubMedCrossRef Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wangler B, Uebleis C et al (2012) The role of 68 Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med 53(11):1686–1692PubMedCrossRef
23.
Zurück zum Zitat Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H et al (2010) The impact of 68 Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 252(5):850–856PubMedCrossRef Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H et al (2010) The impact of 68 Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 252(5):850–856PubMedCrossRef
24.
Zurück zum Zitat Baum RP, Kulkarni HR, Carreras C (2012) Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med 42(3):190–207PubMedCrossRef Baum RP, Kulkarni HR, Carreras C (2012) Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med 42(3):190–207PubMedCrossRef
25.
Zurück zum Zitat Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T et al (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95(2):157–176PubMedCrossRef Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T et al (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95(2):157–176PubMedCrossRef
26.
Zurück zum Zitat Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523PubMedCrossRef Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523PubMedCrossRef
27.
Zurück zum Zitat Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513PubMedCrossRef Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513PubMedCrossRef
28.
Zurück zum Zitat Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656–4663PubMedCrossRef Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656–4663PubMedCrossRef
29.
Zurück zum Zitat Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M et al (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15(4):1083–1097PubMedCrossRef Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M et al (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15(4):1083–1097PubMedCrossRef
30.
Zurück zum Zitat Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G et al (2011) Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29(17):2372–2377PubMedCrossRef Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G et al (2011) Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29(17):2372–2377PubMedCrossRef
31.
Zurück zum Zitat Landerholm K, Zar N, Andersson RE, Falkmer SE, Jarhult J (2011) Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg 98(11):1617–1624PubMedCrossRef Landerholm K, Zar N, Andersson RE, Falkmer SE, Jarhult J (2011) Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg 98(11):1617–1624PubMedCrossRef
32.
Zurück zum Zitat Norlen O, Stalberg P, Oberg K, Eriksson J, Hedberg J, Hessman O et al (2012) Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 36(6):1419–1431. doi:10.1007/s00268-011-1296-z PubMedCrossRef Norlen O, Stalberg P, Oberg K, Eriksson J, Hedberg J, Hessman O et al (2012) Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 36(6):1419–1431. doi:10.​1007/​s00268-011-1296-z PubMedCrossRef
33.
Zurück zum Zitat Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S et al (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12(4):1083–1092PubMedCrossRef Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S et al (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12(4):1083–1092PubMedCrossRef
34.
Zurück zum Zitat Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A et al (2010) Impact of multiphase 68 Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 91(1):101–109PubMedCrossRef Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A et al (2010) Impact of multiphase 68 Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 91(1):101–109PubMedCrossRef
35.
Zurück zum Zitat Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE (2009) Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 96(2):175–184PubMedCrossRef Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE (2009) Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 96(2):175–184PubMedCrossRef
36.
Zurück zum Zitat Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R, Working Group Neuroendocrine Metastasis (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15(1):e8–e21PubMedCrossRef Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R, Working Group Neuroendocrine Metastasis (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15(1):e8–e21PubMedCrossRef
37.
Zurück zum Zitat Yang Z, Tang LH, Klimstra DS (2011) Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 35(6):853–860PubMedCrossRef Yang Z, Tang LH, Klimstra DS (2011) Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 35(6):853–860PubMedCrossRef
38.
Zurück zum Zitat Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O et al (2009) Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol 22(2):273–281PubMedCrossRef Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O et al (2009) Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol 22(2):273–281PubMedCrossRef
39.
Zurück zum Zitat Remes SM, Tuominen VJ, Helin H, Isola J, Arola J (2012) Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am J Surg Pathol 36(9):1359–1363PubMedCrossRef Remes SM, Tuominen VJ, Helin H, Isola J, Arola J (2012) Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am J Surg Pathol 36(9):1359–1363PubMedCrossRef
40.
Zurück zum Zitat Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS (2012) Objective quantification of the Ki-67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 36(12):1761–1770PubMedCrossRef Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS (2012) Objective quantification of the Ki-67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 36(12):1761–1770PubMedCrossRef
41.
Zurück zum Zitat Young HT, Carr NJ, Green B, Tilley C, Bhargava V, Pearce N (2013) Accuracy of visual assessments of proliferation indices in gastroenteropancreatic neuroendocrine tumours. J Clin Pathol 66(8):700–704PubMedCrossRef Young HT, Carr NJ, Green B, Tilley C, Bhargava V, Pearce N (2013) Accuracy of visual assessments of proliferation indices in gastroenteropancreatic neuroendocrine tumours. J Clin Pathol 66(8):700–704PubMedCrossRef
42.
Zurück zum Zitat Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA et al (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319):1109–1113PubMedCentralPubMedCrossRef Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA et al (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319):1109–1113PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J et al (2011) Tumour evolution inferred by single-cell sequencing. Nature 472(7341):90–94PubMedCrossRef Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J et al (2011) Tumour evolution inferred by single-cell sequencing. Nature 472(7341):90–94PubMedCrossRef
44.
Zurück zum Zitat Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892PubMedCrossRef Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892PubMedCrossRef
45.
Zurück zum Zitat Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291):999–1005PubMedCentralPubMedCrossRef Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291):999–1005PubMedCentralPubMedCrossRef
46.
Zurück zum Zitat Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1147PubMedCentralPubMedCrossRef Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1147PubMedCentralPubMedCrossRef
47.
Zurück zum Zitat Habal N, Sims C, Bilchik AJ (2000) Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol 75(4):310–316PubMed Habal N, Sims C, Bilchik AJ (2000) Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol 75(4):310–316PubMed
48.
Zurück zum Zitat Kothari T, Mangla JC (1981) Malignant tumors associated with carcinoid tumors of the gastrointestinal tract. J Clin Gastroenterol 3(Suppl 1):43–46PubMedCrossRef Kothari T, Mangla JC (1981) Malignant tumors associated with carcinoid tumors of the gastrointestinal tract. J Clin Gastroenterol 3(Suppl 1):43–46PubMedCrossRef
49.
Zurück zum Zitat Kim JY, Jang WY, Heo MH, Lee KK, Do YR, Park KU et al (2012) Metachronous double primary cancer after diagnosis of gastric cancer. Cancer Res Treat 44(3):173–178PubMedCentralPubMedCrossRef Kim JY, Jang WY, Heo MH, Lee KK, Do YR, Park KU et al (2012) Metachronous double primary cancer after diagnosis of gastric cancer. Cancer Res Treat 44(3):173–178PubMedCentralPubMedCrossRef
50.
Zurück zum Zitat Liu L, Lemmens VE, De Hingh IH, de Vries E, Roukema JA, van Leerdam ME et al (2013) Second primary cancers in subsites of colon and rectum in patients with previous colorectal cancer. Dis Colon Rectum 56(2):158–168PubMedCrossRef Liu L, Lemmens VE, De Hingh IH, de Vries E, Roukema JA, van Leerdam ME et al (2013) Second primary cancers in subsites of colon and rectum in patients with previous colorectal cancer. Dis Colon Rectum 56(2):158–168PubMedCrossRef
51.
Zurück zum Zitat Watanabe M, Kochi M, Fujii M, Kaiga T, Mihara Y, Funada T et al (2012) Dual primary gastric and colorectal cancer: is the prognosis better for synchronous or metachronous? Am J Clin Oncol 35(5):407–410PubMedCrossRef Watanabe M, Kochi M, Fujii M, Kaiga T, Mihara Y, Funada T et al (2012) Dual primary gastric and colorectal cancer: is the prognosis better for synchronous or metachronous? Am J Clin Oncol 35(5):407–410PubMedCrossRef
52.
Zurück zum Zitat Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM (2011) The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 396(3):273–298PubMedCrossRef Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin IM (2011) The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 396(3):273–298PubMedCrossRef
53.
Zurück zum Zitat Zucker KA, Longo WE, Modlin IM, Bilchik AJ, Adrian TE (1989) Malignant diathesis from jejunal-ileal carcinoids. Am J Gastroenterol 84(2):182–186PubMed Zucker KA, Longo WE, Modlin IM, Bilchik AJ, Adrian TE (1989) Malignant diathesis from jejunal-ileal carcinoids. Am J Gastroenterol 84(2):182–186PubMed
54.
Zurück zum Zitat Reubi JC, Gugger M, Waser B, Schaer JC (2001) Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 61(11):4636–4641PubMed Reubi JC, Gugger M, Waser B, Schaer JC (2001) Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 61(11):4636–4641PubMed
55.
Zurück zum Zitat Chave HS, Gough AC, Palmer K, Preston SR, Primrose JN (2000) Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa. Br J Cancer 82(1):124–130PubMedCentralPubMedCrossRef Chave HS, Gough AC, Palmer K, Preston SR, Primrose JN (2000) Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa. Br J Cancer 82(1):124–130PubMedCentralPubMedCrossRef
Metadaten
Titel
Role of Ki-67 Proliferation Index in the Assessment of Patients with Neuroendocrine Neoplasias Regarding the Stage of Disease
verfasst von
H. C. Miller
P. Drymousis
R. Flora
R. Goldin
D. Spalding
A. Frilling
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
World Journal of Surgery / Ausgabe 6/2014
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-014-2451-0

Weitere Artikel der Ausgabe 6/2014

World Journal of Surgery 6/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.